Medana

Anita Bruen

🇪🇸 Spain

9.1

Reviewed: August 11, 2023

• - Clinical Data Management
• - 6 weeks June - July 2023
• - CRO

The data management services were delivered on time and with great accuracy. Collaboration with the team was smooth, and they were always available to address any concerns or questions we had. We were very satisfied with the outcome.

Karen Douglas DVM

🇷🇺 Russia

9.2

Reviewed: January 10, 2024

• - Data Visualization
• - 3 weeks December 2023
• - Pharmaceutical Company

The data visualization services were highly effective, making complex data easy to interpret and communicate. The visualizations were impactful and played a crucial role in our stakeholder presentations.

Kara Walter

🇸🇦 Saudi Arabia

9

Reviewed: June 9, 2024

• - Process Development
• - 12 weeks March - May 2024
• - Biotech Company

The process development services enhanced our manufacturing efficiency significantly. The team's expertise in process optimization was evident, and they provided valuable insights that improved our production workflow.

Amelia Kozey

🇬🇧 United Kingdom

9.3

Reviewed: March 12, 2024

• - Market Access Strategy
• - 6 weeks January - February 2024
• - Pharmaceutical Company

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Wanda Gutkowski V

🇹🇷 Turkey

6.2

Reviewed: March 15, 2024

• - Clinical Protocol Design
• - 10 weeks January - March 2024
• - Pharmaceutical Company

The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.

Leroy Veum

🇸🇦 Saudi Arabia

5.7

Reviewed: June 10, 2024

• - Project Management
• - 12 weeks March - May 2024
• - Biotech Company

Communication from the project management team was poor, with frequent missed deadlines. This caused significant frustration on our end, as we had to repeatedly chase them for updates. The project eventually got back on track, but the delays were problematic.

Tracy Labadie

🇲🇽 Mexico

6.3

Reviewed: November 7, 2024

• - Stability Studies
• - 16 months July 2023 - November 2024
• - Pharmaceutical Company

The stability studies conducted were lacking in detail, and we had to perform additional validation to ensure the results were reliable. This added extra time and cost to the project. The team was responsive to feedback, but the initial work was subpar.

Melissa Funk IV

🇬🇧 United Kingdom

8.9

Reviewed: July 3, 2024

• - Stability Studies
• - 18 months January 2023 - June 2024
• - Pharmaceutical Company

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Dr. Everett McKenzie

🇳🇱 Netherlands

6

Reviewed: September 12, 2024

• - Health Technology Assessment
• - 8 weeks July - September 2024
• - Pharmaceutical Company

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.

Geoffrey Boyer

🇨🇳 China

9

Reviewed: June 18, 2023

• - Clinical Protocol Design
• - 6 weeks April - May 2023
• - Pharmaceutical Company

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.